reports
- Mathijs Geerts Danau
Inventiva Raises $ 150m gross proceeds in a public offering
Inventiva announced the issuance of ~39m new ADSs in a public offering in the US at an issue price of $ 3.85 per ADS (approx. 0.9% discount to the VWAP of Euronext trading the previous day) resulting in gross proceeds of $ ~150m and net proceeds of € ~121m. Inventiva's cash runway is extended to at least 1Q27 (previously 3Q26), assuming no Tranche 3 warrants will be issued. We plan to incorporate the new share capital and cash in our target price in the future. We view this raise as a positive a...
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
Inventiva announces trading resumption of its ordinary shares on Euron...
Inventiva announces trading resumption of its ordinary shares on Euronext Paris Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). Trading of the ordinary shares of the Company was halted, at the Comp...
Inventiva annonce la reprise des négociations de ses actions ordinaire...
Inventiva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé la reprise des négociations de ses actions ordinaires sur le marché réglementé de Euronext à Paris aujourd’hui à compter de 16h30 (CET). La négociation des actions ...
Inventiva announces pricing of upsized public offering of approximatel...
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), ea...
Inventiva annonce les modalités définitives ainsi que l'extension de l...
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au public d'American Depositary Shares d'approximativement 150 millions de dollars Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la fixation des modalités définitives de l'offre au public préalablement annoncée, au...
- Jerôme Bodin
ZIL2 ELRINGKLINGER AG
SBMO SBM OFFSHORE NV
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
PSM PROSIEBENSAT.1 MEDIA SE
HOT HOCHTIEF AG
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
SIX2 SIXT SE
WIE WIENERBERGER AG
CWC CEWE STIFTUNG & CO KGAA
SEM SEMPERIT HOLDING AG
COK CANCOM SE
DLG DE'LONGHI S.P.A.
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PYT POLYTEC HOLDING
FYB FORMYCON AG
DUE DURR AG
DMP DERMAPHARM HOLDING SE
S92 SMA SOLAR TECHNOLOGY AG
JEN JENOPTIK AG
UPG UNIFIEDPOST GROUP
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
FORSE FORSEE POWER SA
DEME DEME GROUP NV
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
- Jerôme Bodin
ZIL2 ELRINGKLINGER AG
SBMO SBM OFFSHORE NV
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
PSM PROSIEBENSAT.1 MEDIA SE
HOT HOCHTIEF AG
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
SIX2 SIXT SE
WIE WIENERBERGER AG
CWC CEWE STIFTUNG & CO KGAA
SEM SEMPERIT HOLDING AG
COK CANCOM SE
DLG DE'LONGHI S.P.A.
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PYT POLYTEC HOLDING
FYB FORMYCON AG
DUE DURR AG
DMP DERMAPHARM HOLDING SE
S92 SMA SOLAR TECHNOLOGY AG
JEN JENOPTIK AG
UPG UNIFIEDPOST GROUP
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
FORSE FORSEE POWER SA
SPAC 468 SPAC I SE
DEME DEME GROUP NV
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
- Mathijs Geerts Danau
Inventiva Launches capital increase for gross proceeds of € 108m
Inventiva announced the launch of a capital increase by way of underwritten public offering of ADSs in the US. The company intends to raise € 108m and will use the proceeds to fund the continuation of the phase 3 trial, and prepare for commercialization and an outcomes trial. We view this raise as a positive and reiterate our BUY rating and € 8 TP.
- ING Helpdesk
Benelux Morning Notes
AEGON: 3Q in line, UK weak, all eyes on CMD in December. DEME Group: Going into 2026 with a stable order book. D'Ieteren: North America Beron peer Boyd confirms positive l/l in 3Q25, further improvement in 4Q25. KBC: 3Q above, increase in FY25 guidance across the board, first SRT is sizeable. Ontex: Peer Essity acquires Edgewell's Feminine Care activity. SBM Offshore: Progression in markets and earnings. Zabka: CVC and PG sell 100m shares via ABB
- Guy Sips
Agfa Decline in medical film was even stronger than expected
Agfa's 3Q25 continued decline in medical film was even stronger than expected (€ 257m 3Q25 sales vs € 275m KBCS & CSS). Although the growth in cloud/SaaS in HealthCare IT all the divisions were below our and CSS forecasts as well on top-line as on REBIT-margins. The increase in Digital Printing & Chemicals was not sufficiently offsetting the impact from the decline in medical film and from cloud transition in HealthCare IT. Despite good cost control, REBIT decreased to -4m, mainly due to the d...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Inventiva announces temporary trading halt of its ordinary shares on E...
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company’s request, from the opening of the mar...
Inventiva annonce la suspension temporaire du cours de ses actions ord...
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui que le cours de bourse de ses actions ordinaires sur le marché réglementé d'Euronext à Paris (« Euronext Paris ») sera temporairement suspendu, à sa ...
- Guy Sips
DEME Although 3Q was weaker y/y another record year is taking shape
As 3Q25 turnover was € 980.9m (-9% y/y also impacted by a strong comparison base), 9M25 turnover surpassed €3bn, still a 3% y/y increase. Although y/y all segments had lower revenues in 3Q (-6% for Dredging & Intra, -12.7% for Offshore Energy, -16.3% for Environmental), DEME indicated that the YtD performance is fuelled by a double-digit YtD growth in the Offshore Energy segment which more than offset softer topline results in other segments compared to strong prior year revenues. Given this 9...
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, ...
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Regulated information November 13, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Group performance: Top line decrease of 7.1% (-4.7% currency comparable): increase in Digital Printing & Chemicals not sufficiently offsetting impact from decline in medical...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende ach...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Gereglementeerde informatie 13 november 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Groepsprestatie: Omzetdaling van 7,1% (-4.7% zonder wisselkoerseffecten): stijging ...
Trading update Q3 2025: another record year taking shape
Trading update Q3 2025: another record year taking shape Highlights third quarter 2025 Group nine-month turnover surpassed 3 billion euros, a 3% increase year-over-yearOrder book is 7.5 billion euros, compared to 7.1 billion euros last yearManagement reiterates its expectations that full-year turnover will be at least in line with 2024 and forecasts a strong year-over-year EBITDA improvement, with the EBITDA margin in the range of 20% to 22%DEME took delivery of its new offshore installation vessel Norse Wind in October, completed on schedule, and set to commence operations in the first ha...
Trading update Q3 2025: een nieuw recordjaar krijgt vorm
Trading update Q3 2025: een nieuw recordjaar krijgt vorm Hoogtepunten derde kwartaal 2025 De groepsomzet over negen maanden overschreed 3 miljard euro, een stijging met 3% jaar over jaarHet orderboek bedroeg 7,5 miljard euro, tegenover 7,1 miljard euro vorig jaarHet management bevestigt opnieuw zijn verwachting dat de omzet voor het volledige jaar minstens in lijn zal liggen met 2024 en verwacht een sterke verbetering van de EBITDA, met de EBITDA-marge in de range van 20% tot 22%DEME’s nieuwe offshore installatieschip Norse Wind werd volgens planning in oktober opgeleverd, en zal in de eer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.